Catherine M. Diefenbach, MD

  • Specialties: Hematology, Leukemia & Lymphoma, Bone Marrow Transplant, Oncology
  • Languages: English, German
  • Phone: 212-731-5670

About Me

I am a hematologist-oncologist specializing in the care of patients with lymphoma. My goal is to provide the best possible care for these patients, and to discover new and scientifically grounded treatments that can improve management and increase the cure rate of lymphoma.

As an oncologist, I am committed to combining compassionate and personalized patient care with cutting-edge, patient-focused, and translational research. I strive to develop a treatment plan for each patient that is designed to fit the person’s unique situation, as well as the biology of his or her tumor.

At NYU Langone’s Perlmutter Cancer Center, our team of experts from various specialties provides outstanding and compassionate clinical care to people with all types of lymphoma. We have the advantage of being at the forefront of advanced research, coupling personalized care with some of the most innovative and groundbreaking clinical trials in the nation. We provide people with access to many exciting new treatments before they are commercially available.

I am currently leading a national clinical trial for patients with relapsed Hodgkin lymphoma. I also serve as the principal investigator for numerous clinical trials at NYU Langone involving a range of different therapies, including targeted therapy, immunotherapy, and radiation therapy. Many of these clinical trials explore innovative methods of combining new targeted or immune-based therapies with existing therapies to find new ways to control lymphoma, while maximizing patients’ quality of life and minimizing side effects. I also collaborate with basic scientists to create the next generation of therapeutic approaches for the management of lymphoma.

I am on the lymphoma committee of the ECOG-ACRIN Cancer Research Group, a cooperative group made up of the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network. I am currently participating in the American Society of Clinical Oncology’s yearlong Leadership Development Program. I have received research grants for my work from the National Cancer Institute, the American Cancer Society, and the Lymphoma Research Foundation.

Conditions and Treatments

non Hodgkin's lymphoma (NHL), Hodgkin disease (HD), cutaneous t-cell lymphoma, AIDS-related lymphoma, blood cancer


  • Assistant Professor, Department of Medicine
Board Certifications
  • American Board of Internal Medicine (Hematology), 2010
  • American Board of Internal Medicine (Medical Oncology), 2008
Education and Training
  • Fellowship, Memorial Sloan-Kettering Cancer Center, Hematology-Oncology, 2008
  • Residency, Johns Hopkins Hospital, Internal Medicine, 2004
  • MD from University Of Pennsylvania, 2001

Locations and Appointments

69 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Agewell
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Exchange
  • Fidelis Family Health
  • Fidelis Medicaid
  • Fidelis Medicare
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP Family Health
  • HIP Medicaid
  • HIP Medicare
  • HealthSmart (WTC)
  • Healthfirst
  • Humana Medicare
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MetroPlus Medicare
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Exchange
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • Tricare
  • UPN Elite
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Village Caremax
  • Visiting Nurse Service (VNS) Medicare
  • WellCare Child Health
  • WellCare Family Health
  • WellCare Medicaid
  • WellCare Medicare
  • Wellcare Exchange
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
NYU Hematology Associates

240 East 38th Street
New York, NY 10016


Phone: 212-731-5670

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.


  • Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. [Meeting Abstract]

    Advani, Ranjana H; Flinn, Ian; Sharman, Jeff Porter; Diefenbach, Catherine SMagid; Kolibaba, Kathryn S; Press, Oliver W; Sehn, Laurie Helen; Chen, Andy I; Salles, Gilles A; Tilly, Herve; Cheson, Bruce D; Assouline, Sarit E; Dreyling, Martin H; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Cheryl; Chu, Yu-Waye; Hirata, Jamie; Wenger, Michael; Morschhauser, Franck
    Journal of clinical oncology. 2015 MAY 20. 33 (15): ?-?

  • A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). [Meeting Abstract]

    Diefenbach, Catherine SMagid; Li, Hailun; Kahl, Brad S; Robertson, Michael J; Cohen, Jonathan; Advani, Ranjana H; Ambinder, Richard; Fenske, Timothy S; Ansell, Stephen Maxted
    Journal of clinical oncology. 2015 MAY 20. 33 (15): ?-?

  • A phase 1 study of PI3Kdelta inhibitor INCB040093 alone or in combination with selective JAK1 inhibitor INCB039110 in patients with relapsed/refractory hodgkin lymphoma [Meeting Abstract]

    Forero-Torres, A; Barr, P M; Magid, Diefenbach C S; Sher, T; Schaub, R; Zhou, L; Pulini, J; Leopold, L; Spear, M A; Talpaz, M; Phillips, T J
    Hematological oncology. 2015 June 2015. 33: 157-157

Read All Publications (36)